Publications 2024

Haakensen VD, Öjlert ÅK, Thunold S, Farooqi S, Nowak AK, Chin WL, Grundberg O, Szejniuk WM, Cedres S, Sørensen JB, Dalen TS, Lund-Iversen M, Bjaanæs M, Helland Å (2024)
UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial
Eur J Cancer, 202, 113973
DOI 10.1016/j.ejca.2024.113973, PubMed 38447379

Publications 2021

Farooqi SJ, Bjaanæs MM, Helland Å, Haakensen VD (2021)
[Immunotherapy for malignant pleural mesothelioma]
Tidsskr Nor Laegeforen, 141
DOI 10.4045/tidsskr.21.0503, PubMed 34505475

Farooqi SJ, Helland A, Haakensen VD, Bjaanaes MM (2021)
Immunotherapy in malignant pleural mesothelioma
Tidsskr. Nor. Laegeforen., 141 (12), 1167-1169

Haakensen VD, Nowak AK, Ellingsen EB, Farooqi SJ, Bjaanæs MM, Horndalsveen H, Mcculloch T, Grundberg O, Cedres SM, Helland Å (2021)
NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
J Transl Med, 19 (1), 232
DOI 10.1186/s12967-021-02905-3, PubMed 34059094